Searched for
GAVIS ACQUISITION
Lupin Q3 results: Loss widens to Rs 835 crore on higher taxTax expenses for the quarter jumped to Rs 767 crore from Rs 245.40 crore.- Lupin CFO quits, to pursue opportunities outside pharmaSwaminathan as the CFO of Lupin, was part of some of company's biggest mergers and acquisition in US and Japan
- Lupin makes impairment provision for GavisLupin took a hit worth Rs 1,464.35 crore on US-based Gavis, which it acquired in 2015 for $880 million (Rs 5,610 crore then).
- Lupin reports Rs 777 crore Q4 loss on one-time impairment provisionsThe company had reported Rs 707 crore profit for the year-ago quarter.
- Lupin's US arm takes over Symbiomix TherapeuticsLupin had entered into an arrangement to acquire the company earlier this year.
- Current headwinds to help shape M&A contours for Indian pharmaDrugmakers have reported impairments, reduced revenue guidance, or stretched the payback time.
- Lupin net skids, says Gavis deal ‘shy’ of expectationsThe business fell 13.2% to Rs 1,900.7 crore from a year earlier and contributed 46% of sales.
- Stock pick of the week: Why analysts are bullish on LupinIn addition to growth in sales in respective markets, favourable currency movement has also helped Lupin to achieve high growth.
- Lupin looks to launch 25 products in US this fiscalIn the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzic...
- GAVIS Pharma LLC looking to exit Bengaluru-based Wintac LtdGavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...
- Selling Lupin with a target at Rs 1602: Karvy Stock BrokingKarvy downgraded their EPS by 7.3%/10.6% to Rs 65.8/Rs 72.8 for FY17E/FY18E respectively due to amortization on account of Gavis acquisition
- Lupin launches generic insomnia drug in USDrug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.
- Lupin completes acquisition of GAVIS PharmaThe acquisition enhances the company's scale in the US generic market and also broadens its pipeline in dermatology and controlled substanc...
- Lupin to invest in Japan; eyes 20 launchesLupin, one of India's top five pharmaceutical companies, is planning to make significant investments in Japan, the second biggest pharmaceu...
- Lupin, Gavis to sell 2 drugs to fulfil US FTC conditionThe acquisition creates the fifth largest portfolio of abbreviated new drug application (ANDA) filings with the USFDA, addressing a USD 63....
- It may take another quarter for Lupin to post a robust showMumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.
- Buyouts unlikely to harm debt-free Lupin's healthWith no new blockbuster drugs going off patent in the near term, generic pharma companies have to explore new areas of growth like specialt...
- JPMorgan to fund Lupin’s $880-million Gavis dealThe loan, it’s understood, is not backed by hard collateral or claims on future cashflow, but based on pure credit assessment.
- Rising local sales, strong drug pipeline may nurse Lupin back to healthAfter a stellar show in earlier years, where it grew an average 20 per cent annually , it has been difficult for Lupin to sustain growth.
- Lupin buys US generics firm Gavis for Rs 5606 croreThe deal, which is cash-free and debt-free, widens the company's pipeline in dermatology and controlled substance products, Lupin said.
Load More
